ProCE Banner Activity

Expert Answers to Clinician Questions on Immune Checkpoint Inhibitors for HCC

Clinical Thought
Read expert answers to audience questions from a live Webcast focused on current and emerging investigational uses of immune checkpoint inhibitors for HCC.

Released: February 11, 2021

Expiration: February 10, 2022

Share

Faculty

Amit G. Singal

Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Amit G. Singal, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exact Sciences, Exelixis, Glycotest, GRAIL, Merck, Roche/Genentech, and Wako.